By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


King Pharmaceuticals®, Inc. 

501 Fifth Street

Bristol  Tennessee  37620  U.S.A.
Phone: 423-989-8000 Fax: 423-274-8677



Company News
Investment Consultant and Lawyer Accused of Insider Trading Ahead of Pfizer (PFE)'s 2010 Acquisition of King Pharma 8/12/2016 6:45:22 AM
Pfizer Inc. (PFE) to Shed 130 Jobs and Close Former King Pharmaceuticals®, Inc. Plant 8/11/2011 7:30:19 AM
DURECT Corporation (DRRX) Announces King Pharmaceuticals®, Inc.'s ELADUR(R) (TRANSDUR(R)-Bupivacaine) Phase II Study Results in Chronic Low Back Pain 4/12/2011 8:52:19 AM
Pfizer Inc. (PFE) Recalls Pain Drug Acquired in King Pharmaceuticals®, Inc. Deal 3/17/2011 8:41:42 AM
King Pharmaceuticals®, Inc. Announces Final Results of Its Offer to Purchase Convertible Notes 3/1/2011 1:52:35 PM
Pfizer Inc. (PFE) Completes Acquisition Of King Pharmaceuticals®, Inc. 3/1/2011 10:58:46 AM
King Pharmaceuticals®, Inc. Announces Intent to Voluntarily Delist From the New York Stock Exchange 2/8/2011 8:40:34 AM
King Pharmaceuticals®, Inc. Announces Offer to Purchase Any and All of Its Outstanding 1 1/4% Convertible Senior Notes Due 2026 Through a Tender Offer 2/1/2011 8:31:44 AM
Pain Therapeutics (PTIE) Receives $5,000,000 Payment from King Pharmaceuticals®, Inc. 1/28/2011 7:18:35 AM
DURECT Corporation (DRRX), King Pharmaceuticals®, Inc.'s REMOXY(R) New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 1/27/2011 7:40:56 AM